OncoCyte's (OCX) Equal Weight Rating Reiterated at Stephens

Stephens reaffirmed their equal weight rating on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $4.00 price target on the stock. Several other research analysts have also commented on OCX. Benchmark reaffirmed a speculative buy rating and set a $5.00 price objective on […]

Related Keywords

United States , Andrew Arno , Goldman Sachs Group Inc , Oncocyte Corporation , Cubist Systematic Strategies , Oncocyte Company Profile , Vanguard Group Inc , Securities Exchange Commission , Raymond James Financial Services Advisors Inc , Free Report , Cyte Stock Down , Director Andrew Arno , Exchange Commission , Broadwood Partners , James Financial Services Advisors , Sachs Group , Get Free Report , Cyte Corporation , Oncocyte Daily , Oncocyte , Nasdaq Ocx , Socx , Medical , Reiterated Rating , Stephens ,